GSK completes acquisition of Aiolos Bio for up to $1.4 bln


LONDON, Feb 15 (Reuters) - GSK GSK.L said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.

GSK will pay $1 billion upfront and up to $400 million in success-based milestone payments.

"In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Jiangsu Hengrui Pharmaceuticals Co, Ltd 600276.SS," the group said.

(Reporting by Pablo Mayo Cerqueiro; editing by Jason Neely)


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.